Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110380

Reactivity of a monoclonal antibody with human ovarian carcinoma.

R C Bast Jr, M Feeney, H Lazarus, L M Nadler, R B Colvin, and R C Knapp

Find articles by Bast, R. in: JCI | PubMed | Google Scholar

Find articles by Feeney, M. in: JCI | PubMed | Google Scholar

Find articles by Lazarus, H. in: JCI | PubMed | Google Scholar

Find articles by Nadler, L. in: JCI | PubMed | Google Scholar

Find articles by Colvin, R. in: JCI | PubMed | Google Scholar

Find articles by Knapp, R. in: JCI | PubMed | Google Scholar

Published November 1, 1981 - More info

Published in Volume 68, Issue 5 on November 1, 1981
J Clin Invest. 1981;68(5):1331–1337. https://doi.org/10.1172/JCI110380.
© 1981 The American Society for Clinical Investigation
Published November 1, 1981 - Version history
View PDF
Abstract

A murine monoclonal antibody (OC125) has been developed that reacts with each of six epithelial ovarian carcinoma cell lines and with cryopreserved tumor tissue from 12 of 20 ovarian cancer patients. By contrast, the antibody does not bind to a variety of nonmalignant tissues, including adult and fetal ovary. OC125 reacts with only 1 of 14 cell lines derived from nonovarian neoplasms and has failed to react with cryostat sections from 12 nonovarian carcinomas.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1331
page 1331
icon of scanned page 1332
page 1332
icon of scanned page 1333
page 1333
icon of scanned page 1334
page 1334
icon of scanned page 1335
page 1335
icon of scanned page 1336
page 1336
icon of scanned page 1337
page 1337
Version history
  • Version 1 (November 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts